In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China is now setting the pace in life sciences R&D, conducting more clinical trials than the U.S. and licensing new ...

Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Now, many are returning to China, taking their skills, experience and professional contacts with them. The time is right for Western biotech and pharma companies to invest in and train a homegrown ...

Keros will also stop work on a cardiovascular disease drug. Elsewhere, Stealth Biotherapeutics and Taysha Gene Therapies each ...

The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.

Home-grown start-up Mirxes is going places, but co-founder is firmly rooted in Singapore. Read more at straitstimes.com. Read ...

While MIC2025 was officially shelved from public discourse in 2018 due to intense international backlash, its core objectives ...